19.09.2023 - BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) - Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today . Seite 1
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive.
Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and.
Adventures of Heme cartoon aims to draw more Black kids to science - San Francisco Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.